Rapid Assessment of Drug Abuse: Smart City Tools (R43/R44 - Clinical Trial Optional) | RFA DA 20 021

Opportunity Information: Apply for RFA DA 20 021

The Rapid Assessment of Drug Abuse: Smart City Tools (R43/R44 - Clinical Trial Optional) funding opportunity (RFA-DA-20-021) is a National Institutes of Health (NIH) small business grant program focused on developing practical, market-ready technologies that strengthen how communities monitor illicit drug use through wastewater testing. The central idea is to move wastewater-based drug monitoring from an occasional, retrospective measurement into a more dynamic, near-real-time public health tool that can better inform local decision-making. By emphasizing "smart city tools," the opportunity is aiming for technology that can be integrated into modern municipal infrastructure and data systems, helping public health and public safety partners detect changes in drug consumption patterns more quickly and respond more effectively.

This announcement uses the SBIR Phased Innovation mechanism (R43/R44), meaning it is specifically designed for small businesses and it supports research and development with clear commercialization potential. Phase I (R43) typically supports early-stage feasibility and proof-of-concept work, while Phase II (R44) supports more advanced development, validation, and steps toward productization and market entry. The "clinical trial optional" label signals that applicants may propose studies that meet NIH's definition of a clinical trial if appropriate, but they are not required to do so. In practice, many wastewater-monitoring technology projects may not involve clinical trials at all, but the flexibility is there in case the proposed work includes human-subject-related endpoints or prospective interventions that fall under NIH clinical trial criteria.

The technical focus is on improving the utilization of wastewater testing for monitoring illicit drugs. Wastewater testing (often called wastewater-based epidemiology) can estimate community-level drug consumption by measuring drug metabolites and related chemical markers in sewage. What NIH is seeking here are tools and approaches that make this monitoring more actionable and scalable: improvements that increase sensitivity and specificity for drug detection, reduce turnaround time, allow more frequent sampling, automate or simplify sample processing, improve data interpretation, and enable rapid reporting. Strong applications under this type of program generally propose solutions that help translate raw chemical measurements into operational insights for cities, such as detecting spikes linked to emerging drug threats, evaluating the impact of policy or enforcement changes, or providing early warning of overdose-risk trends. The "smart city" angle also suggests interest in systems that pair sampling hardware with analytics, dashboards, and secure data pipelines so that results can be used by authorized stakeholders without requiring specialized laboratory expertise at every step.

From an eligibility standpoint, the opportunity is restricted to small businesses, consistent with the SBIR program rules. Foreign institutions are explicitly not eligible to apply, and non-U.S. components of U.S. organizations are also not eligible to apply. However, "foreign components" as defined in the NIH Grants Policy Statement may be allowed, meaning some limited foreign collaboration or performance of specific project elements outside the U.S. could be permitted if properly justified and compliant with NIH policy, but the applicant organization itself must be an eligible U.S. small business and the project structure must follow NIH requirements.

Administratively, the opportunity is categorized as discretionary funding and uses a grant funding instrument. It falls within NIH’s health-related funding activity (and is listed under CFDA number 93.279, associated with drug abuse and addiction research programming). The original closing date listed for applications was 2019-08-07, and the record shows a creation date of 2019-05-15. An award ceiling and expected number of awards are not specified in the provided source fields, which is not unusual for some NIH FOA summaries; actual budgets and award counts are often determined by the quality of applications received, availability of funds, and program priorities.

Overall, this FOA is best understood as an applied research and product development opportunity for small businesses that can deliver deployable wastewater-based drug monitoring solutions. Competitive projects would typically show a clear path from a technical innovation (for example, improved sampling devices, on-site detection methods, automated lab workflows, or advanced analytics) to a real-world implementation model, including considerations like cost, reliability, scalability across different sewer systems, data quality controls, and how results can be used responsibly by public agencies. The end goal is not just better measurement, but faster, more useful information that supports community-level responses to illicit drug trends.

• The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Rapid Assessment of Drug Abuse: Smart City Tools (R43/R44 - Clinical Trial Optional)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279.
• This funding opportunity was created on 2019-05-15.
• Applicants must submit their applications by 2019-08-07. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: Small businesses.

Apply for RFA DA 20 021

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: